insights_auto
Parashikimi: 48.6% optimist·0.0% pesimist
Shko tek analizachevron_right
GILD:NASDAQ
Gilead Sciences, Inc
156,19 US$
arrow_downward
-0,75%(-1,18) 1D
156,84 US$
arrow_upward
+0,42% (+0,65)bedtimeJashtë orarit
Mbyllur: 16 tet, 4:00:02 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për GILD...
Hap
157,32 US$
I lartë
157,58 US$
I ulët
155,62 US$
Kapitalizimi i tregut
193,67 mld
Vëllimi mesatar
5,79 mln
Vëllimi
7,77 mln
Dividendi
2,10%
Dividendi tremujor
0,82 US$
Data e ndërprerjes së dividendit
15 sht 2026
Maksimumi 52-javor
160,51 US$
Minimumi 52-javor
114,02 US$
Fitimet për aksion
-2,66 US$
Beta
0,32
Aksionet në qarkullim
1,24 mld
Numri i punonjësve
17 mijë
Hap
157,32 US$
I lartë
157,58 US$
I ulët
155,62 US$
Kapitalizimi i tregut
193,67 mld
Vëllimi mesatar
5,79 mln
Vëllimi
7,77 mln
Dividendi
2,10%
Dividendi tremujor
0,82 US$
Data e ndërprerjes së dividendit
15 sht 2026
Maksimumi 52-javor
160,51 US$
Minimumi 52-javor
114,02 US$
Fitimet për aksion
-2,66 US$
Beta
0,32
Aksionet në qarkullim
1,24 mld
Numri i punonjësve
17 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Simply Wall Street
·
7 orë më parë
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Investing.com Nigeria
·
9 orë më parë
Gilead chairman & CEO O’Day sells $2.2m in stock
MarketBeat
·
12 orë më parë
Gilead Sciences, Inc. $GILD Stock Sold by New England Research & Management Inc.
Stock Traders Daily
·
21 orë më parë
(GILD) Price Dynamics and Execution-Aware Positioning
Profili
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Rreth Gilead Sciences, Inc
Drejtori ekzekutivDaniel O'Day
Punonjësit17 mijë
Themeluar më22 qer 1987
SeliaFoster City, Kalifornia, Shtetet e Bashkuara të Amerikës
Sektori-
Uebsajtigilead.com